The DOCK4 Knockout Jurkat Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human Jurkat T-lymphocyte line, designed to disrupt endogenous DOCK4 expression. This loss-of-function model enables investigation of DOCK4-dependent signaling and cellular processes without direct manipulation of downstream effectors. The polyclonal format preserves genetic heterogeneity, reflecting a population-level gene knockout that is well-suited for initial functional screening and pathway analysis.
Jurkat cells, originally isolated from a patient with acute T-cell leukemia, serve as a widely employed model system for T-cell signaling and adaptive immunity. These cells recapitulate key aspects of TCR-mediated activation, cytokine secretion, and actin-dependent processes such as migration and immunological synapse formation. Their robust growth and genetic tractability make them an optimal host for CRISPR/Cas9-based knockout studies.
DOCK4 functions as a guanine nucleotide exchange factor (GEF) that specifically activates the small GTPase Rac1 by promoting GDP-to-GTP exchange. Activated Rac1 triggers downstream effectors including PAK1 and LIMK1, leading to cofilin inactivation and subsequent ARP2/3-mediated actin polymerization. DOCK4 also directly interacts with ??-catenin, thereby modulating the Wnt/??-catenin transcriptional pathway via TCF/LEF transcription factors. Upstream regulators such as PDGF receptor, Wnt/Frizzled receptors, integrins, and Src kinase converge on DOCK4 to fine-tune Rac1 activity and actin dynamics. Additional interacting partners ELMO1 and ELMO2 facilitate DOCK4-mediated Rac1 activation in a context-dependent manner.
In the Jurkat T-cell background, DOCK4 knockout provides a valuable tool to dissect the molecular control of actin cytoskeleton remodeling during lymphocyte migration and adhesion. Given the importance of Rac1 signaling in T-cell polarization, chemotaxis, and stable conjugate formation with antigen-presenting cells, loss of DOCK4 is expected to alter these processes. Moreover, the implication of Wnt/??-catenin signaling in T-cell development and leukemogenesis positions this knockout model as a relevant system for studying aberrant pathway activation in lymphoid malignancies.
Researchers can employ DOCK4 Knockout Jurkat Polyclonal Cells in transwell migration assays to assess chemotactic responses, in immunofluorescence studies to visualize actin reorganization, and in Rac1 activity assays to quantify GTPase activation. Western blotting and RT-qPCR enable verification of DOCK4 protein and transcript loss, while co-immunoprecipitation can probe ??-catenin and ELMO complex interactions. Flow cytometry facilitates analysis of integrin expression and adhesion molecule profiles. For additional information or to request a quote, please contact Ascent Research.
